Inhibition of the oestradiol-induced increase in adenohypophyseal weight and in hypothalamic and serum polyphenol oxidase activity by dopaminergic agonists

The administration of oestradiol (oestradiol benzoate as an aqueous microcrystal suspension, Agofolin depot SPOFA, 1 mg i.m. twice a week) leads in rats to an increase in adenohypophyseal weight and in polyphenol oxidase activity in the serum (ceruloplasmin) and in the base of the brain (the floor o...

Full description

Saved in:
Bibliographic Details
Published inPhysiologia Bohemoslovaca Vol. 32; no. 2; p. 117
Main Authors Schreiber, V, Pribyl, T, Jahodová, J
Format Journal Article
LanguageEnglish
Published Czech Republic 1983
Subjects
Animals
Body Weight - drug effects
Catechol Oxidase - blood
Ceruloplasmin - analysis
Ergolines - pharmacology
Estradiol - pharmacology
Hypothalamus - drug effects
Hypothalamus - enzymology
Lisuride - pharmacology
Male
Organ Size - drug effects
Pituitary Gland, Anterior - drug effects
Rats
Rats, Inbred Strains
Receptors, Dopamine - drug effects
Online AccessGet more information

Cover

More Information
Summary:The administration of oestradiol (oestradiol benzoate as an aqueous microcrystal suspension, Agofolin depot SPOFA, 1 mg i.m. twice a week) leads in rats to an increase in adenohypophyseal weight and in polyphenol oxidase activity in the serum (ceruloplasmin) and in the base of the brain (the floor of the third ventricle). The simultaneous peroral administration of the ergoline derivatives D-6-methyl-8-ergoline-(i)-yl acetic acid amide (Deprenon SPOFA) or N-(D-6-methyl-8-isoergolenyl)-N',N'-diethyl carbamide hydrogen maleate (lisuride, Lysenyl SPOFA) in a dose of 200 micrograms/rat/day markedly inhibited all three reactions. The two derivatives were equally effective. Inhibition of the increase in hypothalamic polyphenol oxidase activity, with resultant reduced disintegration of hypothalamic dopamine, may play a role in the mechanism of inhibition of the pituitary reaction to oestradiol caused by dopaminergic agonists. The agonists can also, of course, act like dopamine in the adenohypophysis itself.
ISSN:0369-9463